Acumen Pharmaceuticals, Inc.
ABOSDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 11, 2026
5wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
How ABOS's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
sabirnetug | Phase 2 | Alzheimer Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Acumen Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Acumen Pharmaceuticals, Inc.'s (ABOS) pipeline across Phase 2. Its lead program is sabirnetug (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Acumen Pharmaceuticals, Inc.'s next FDA catalyst?→
Acumen Pharmaceuticals, Inc.'s (ABOS) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ABOS biotech catalysts?→
Add ABOS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Acumen Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.